Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05276492 · ClinicalTrials.gov registry record · Phase 1
Decreasing Dosing Regimens of Abiraterone 500 mg in Men With Prostate Cancer to Find Lowest Recommended Dose.
A Phase 1 study, sponsored by University of Chicago.
- Terminated
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
NCT05276492 is a Phase 1 study that was terminated before completion, run by University of Chicago. The registered enrollment target is 50 participants.
The verdict
NCT05276492, a Phase 1 study, was terminated before completion, sponsored by University of Chicago.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
Study Summary
Doctors leading this study plan to collect new information about the lowest effective dose of abiraterone acetate in study participants with prostate cancer who are taking abiraterone in combination with prednisone for the first time. The duration of this study will be about 3 months (12 weeks). How long you stay on abiraterone, and at what dose after completion of the 12 weeks of study drug administration, will be up to you and your treating physician.
Interventions
- DRUG Abiraterone Oral Tablet
- DRUG Prednisone tablet
- OTHER Drug Dairy/Log
- DRUG Low-fat meal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2023-01-24 |
| Est. Completion | 2024-11-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05276492
The ClinicalTrials.gov registry entry for NCT05276492 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Abiraterone Oral Tablet is the first listed.
NCT05276492 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05276492 about?
NCT05276492 is a clinical study titled "Decreasing Dosing Regimens of Abiraterone 500 mg in Men With Prostate Cancer to Find Lowest Recommended Dose.". Doctors leading this study plan to collect new information about the lowest effective dose of abiraterone acetate in study participants with prostate cancer who are taking abiraterone in combination with prednisone for the first time. The duration of this study will be about 3 months (12 weeks). How...
What is the current status of trial NCT05276492?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2023-01-24. Estimated completion is 2024-11-16.
What interventions are being tested in trial NCT05276492?
The interventions under investigation include: Abiraterone Oral Tablet (DRUG), Prednisone tablet (DRUG), Drug Dairy/Log (OTHER), Low-fat meal (DRUG).
Who is sponsoring clinical trial NCT05276492?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.